Related Experiment Video
Updated: Aug 11, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles
Subbaya Subramanian1, Robert B West, Christopher L Corless
1Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA.
Abstract:
Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.
Insights
Gastrointestinal stromal tumors (GISTs) with different KIT or PDGFRA mutations show distinct gene expression patterns. These differences may offer new therapeutic targets for GIST treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastrointestinal stromal tumors (GISTs) often arise from oncogenic activation of KIT or PDGFRA receptor tyrosine kinases.
- The specific type of kinase mutation influences GIST biology and response to imatinib therapy.
- KIT exon 11 mutations are linked to gastric GISTs with good imatinib response, while KIT exon 9 mutations are associated with small bowel GISTs and poorer response.
Purpose of the Study:
- To investigate gene expression differences in GISTs based on their KIT and PDGFRA mutational status.
- To identify potential molecular mechanisms underlying the distinct clinicopathological features of different GIST subtypes.
- To explore novel therapeutic targets associated with specific GIST mutations.
Main Methods:
- Gene expression profiling was performed on 26 GIST samples with known mutational status.
- Expression data was validated using RNA in situ hybridization, immunohistochemistry, and immunoblotting.
- Unsupervised hierarchical clustering was employed to group tumors based on gene expression patterns.
Main Results:
- Hierarchical clustering revealed groupings of tumors with similar mutations, though distinctions were not absolute.
- Differentially expressed genes identified include ezrin, p70S6K, and protein kinase Cs (PKCs).
- These genes play known roles in KIT or PDGFRA signaling pathways.
Conclusions:
- Gene expression profiles correlate with specific KIT and PDGFRA mutation types in GISTs.
- Identified genes like ezrin, p70S6K, and PKCs may contribute to GIST clinicopathological variations.
- These gene products represent potential targeted therapeutic strategies for specific GIST mutational subtypes.
